U.S. Hotel and Resort REITs Stock News

NYSE:AZO
NYSE:AZOSpecialty Retail

Is Rising EPS Projections And Analyst Revisions Altering The Investment Case For AutoZone (AZO)?

In early August 2026, AutoZone drew attention as projections indicated year-over-year earnings-per-share growth ahead of its upcoming results release. The key development is growing investor focus on analyst estimate revisions, which are shaping expectations for AutoZone’s near-term earnings performance. With optimism around stronger projected earnings, we’ll now assess how this focus on estimate revisions affects AutoZone’s broader investment narrative. The latest GPUs need a type of rare...
NYSE:PL
NYSE:PLProfessional Services

Is Planet Labs PBC (PL) Priced For Perfection After Its Huge Run?

Planet Labs PBC stock has delivered a very strong multi year return, yet the valuation checks currently lean expensive, which raises questions about how much upside is already reflected in the US$22.72 share price. Planet Labs PBC has returned roughly 5.6x over the past 3 years, which is a very large move that sets a high bar for further gains. The recent award from the Scottish Government for AI enabled agricultural monitoring can support confidence in Planet Labs PBC's data platform. At...
NasdaqGS:WTFC
NasdaqGS:WTFCBanks

Wintrust Financial (WTFC) Near $159 Following Strong Run While Valuation Still Looks In Line

Wintrust Financial (WTFC) has drawn investor attention after its recent share price performance, with the stock near $159. This move comes alongside updated return figures across multiple timeframes and is prompting a closer look at current fundamentals. See our latest analysis for Wintrust Financial. Over the past year, Wintrust Financial’s share price return has been solid, while the recent 1 month and 1 week moves show some cooling in short term momentum. At the same time, longer term...
NYSE:PRU
NYSE:PRUInsurance

Prudential Financial Stock And 2 Income Plays Investors Are Rechecking After The Fed

The Fed’s shift to “less guidance” and a July jobs report that could jolt expectations on rates have put income portfolios under a sharper spotlight. With markets now reacting more directly to every data point, reliable dividend payers can look more appealing yet also more exposed to interest rate swings. This article walks through three high dividend stocks tied to this theme and how the latest policy backdrop might affect them. The three stocks highlighted below are only a sample of what...
NYSE:LMND
NYSE:LMNDInsurance

Lemonade (LMND) Names A New CFO, Does The Stock Look Fully Valued?

Lemonade (LMND) has drawn fresh attention after the company combined a planned chief financial officer transition with its latest quarterly earnings update. Both leadership and operating metrics are now in clearer focus for investors. See our latest analysis for Lemonade. The latest CFO transition news and stronger quarterly revenue came against a volatile backdrop for Lemonade, with the 7 day share price return of 6.77% partly offsetting a 30 day share price decline of 33.16%. Over longer...
NYSE:FNF
NYSE:FNFInsurance

Earnings Beat, Dividend Hike, and Buybacks Could Be a Game Changer For Fidelity National Financial (FNF)

Fidelity National Financial, Inc. recently reported that for Q2 2026 revenue rose to US$4.05 billion and net income reached US$288 million, while its board declared a quarterly cash dividend of US$0.52 per share payable on September 30, 2026 to shareholders of record on September 16, 2026. The company also completed US$390.19 million of share repurchases under its August 2024 program, alongside year-over-year gains in adjusted pretax title earnings and margins and record assets under...
NYSE:CAH
NYSE:CAHHealthcare

Did Levothyroxine Recalls and a New CAO Just Shift Cardinal Health's (CAH) Risk Narrative?

In early August 2026, Cardinal Health disclosed that Major Pharmaceuticals, a Cardinal-affiliated distributor, voluntarily initiated ongoing nationwide Class II recalls of certain subpotent levothyroxine tablet lots, while also announcing that former Baxter and Sysco finance leader Anita Zielinski will become Chief Accounting Officer in November 2026. This combination of a targeted drug recall and an incoming Chief Accounting Officer with extensive Big Four and corporate finance experience...
NYSEAM:TMP
NYSEAM:TMPBanks

Tompkins Financial (TMP) Posted Stronger Earnings And Raised Its Dividend, Is It Still Cheap?

Tompkins Financial (TMP) has drawn fresh investor attention after reporting higher second quarter and first half 2026 earnings, along with a 4.5% increase in its regular quarterly dividend to $0.70 per share. See our latest analysis for Tompkins Financial. At a share price of $99.89, Tompkins Financial has delivered a 30 day share price return of 6.8% and a year to date share price return of 37.76%. Its 1 year total shareholder return of 67.14% and 3 year total shareholder return of 97.92%...
NYSE:PHM
NYSE:PHMConsumer Durables

PulteGroup (PHM) Expands In Northwest Florida, Is The Stock 32% Undervalued?

PulteGroup (PHM) has expanded into Northwest Florida with a new Florida Panhandle Division, tied to a builder agreement for up to 2,653 homesites. This move gives investors fresh context for assessing the stock. See our latest analysis for PulteGroup. The recent Northwest Florida expansion sits alongside a mixed price picture, with the share price down 2.60% over the last day but up 10.21% on a 90 day share price return and supported by a 5 year total shareholder return of 149.49%. This...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

TG Therapeutics (TGTX) Is Down 7.4% After Q2 Profit Drop Despite Higher 2026 Revenue Guidance – Has The Bull Case Changed?

TG Therapeutics, Inc. reported past second-quarter 2026 results with revenue of US$240.34 million versus US$141.15 million a year earlier, while net income declined to US$7.78 million from US$28.19 million and diluted EPS from continuing operations was US$0.05 compared with US$0.17. Despite weaker profitability, management raised full-year 2026 global revenue guidance to approximately US$950 million, underscoring confidence in the commercial trajectory of its B-cell disease franchise. We’ll...
NYSE:HASI
NYSE:HASIDiversified Financial

Is HA Sustainable Infrastructure Capital (HASI) Undervalued On Its Q2 Earnings Beat?

Why HA Sustainable Infrastructure Capital’s latest earnings matter HA Sustainable Infrastructure Capital (HASI) reported second quarter 2026 results that exceeded market expectations on both revenue and earnings per share. The company also highlighted continued demand for its climate focused infrastructure projects. See our latest analysis for HA Sustainable Infrastructure Capital. After the earnings beat and dividend affirmation on 6 August 2026, HA Sustainable Infrastructure Capital’s share...
NasdaqGS:IPAR
NasdaqGS:IPARPersonal Products

Interparfums (IPAR) Is Down 5.2% After Reaffirming 2026 Outlook Amid Margin Pressure And Dividend Declaration

Interparfums, Inc. recently reported second-quarter 2026 results showing sales of US$341.04 million and net income of US$30.49 million, while also declaring a regular quarterly cash dividend of US$0.80 per share payable on September 30, 2026, to shareholders of record on September 15, 2026. Despite modest sales growth and slightly lower earnings, management reaffirmed its full-year 2026 outlook, including expected sales of US$1.48 billion and EPS of US$4.85, and highlighted a robust 2027...
NYSE:DHI
NYSE:DHIConsumer Durables

D.R. Horton (DHI) Looks 12% Undervalued, Is More Upside Still Ahead?

D.R. Horton (DHI) has drawn investor attention after recent share price moves, with the stock down about 6% over the past month and slightly lower over the past year. This shift invites a closer look. See our latest analysis for D.R. Horton. D.R. Horton’s recent 1 day share price decline of 3.6% and 30 day share price return down 6.2% sit against a 5 year total shareholder return of 58.0%. This points to fading near term momentum but a still positive longer term record. If this shift in...
NYSE:KOP
NYSE:KOPChemicals

Koppers Holdings (KOP) Is Up 6.8% After Q2 Loss And Maintained Dividend Decision – What's Changed

Koppers Holdings Inc. reported past second-quarter 2026 results showing sales rising to US$520.1 million from US$504.8 million a year earlier, but swinging from US$16.4 million in net income to a US$147.5 million net loss, while also affirming a quarterly dividend of US$0.09 per share payable in September 2026. Despite the move to a large loss and basic loss per share of US$7.71 from prior earnings of US$0.83, the decision to maintain its dividend suggests management is balancing shareholder...
NasdaqGS:WMT
NasdaqGS:WMTConsumer Retailing

Walmart (WMT) Stock May Trade Above Fair Value After Its 140% Run

Walmart stock has delivered a strong 139.5% return over the past five years, yet current checks suggest investors are now paying a premium to the latest intrinsic value estimate from a Discounted Cash Flow (DCF) model. With analysts recently turning more cautious on near term growth, even as the company pushes into areas like connected TV advertising and drone delivery, pricing looks less straightforward than the recent run might suggest. Over five years, Walmart has returned 139.5%, which...
NasdaqGS:SVC
NasdaqGS:SVCHotel and Resort REITs

Service Properties Trust (SVC) Could Be 262% Overvalued On Q2 Losses

Why Service Properties Trust’s Latest Earnings Matter For Investors Service Properties Trust (SVC) has drawn fresh attention after reporting second quarter 2026 results, with revenue of $420.97 million and a net loss of $223.84 million compared with the prior year period. See our latest analysis for Service Properties Trust. The earnings release on 5 August has arrived after a mixed period for Service Properties Trust, with the share price up 7.23% on the day, while the year-to-date share...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

Is CrowdStrike Holdings (CRWD) Fully Valued As Fal.Con 2026 And Its AI Security Challenge Draw Interest?

Why Fal.Con 2026 and AI security experiments matter for CrowdStrike stock CrowdStrike Holdings (CRWD) has drawn fresh attention after Fal.Con 2026 sold out faster than prior years and the company launched a global AI security challenge with Amazon Web Services. Both initiatives sit at the intersection of cybersecurity and artificial intelligence, a theme many investors already link closely with CrowdStrike. They also arrive only weeks before the company’s next earnings release on August 26,...
NasdaqCM:XPEL
NasdaqCM:XPELAuto Components

Why XPEL (XPEL) Is Up 8.0% After Raising EPS And Revenue Guidance - And What's Next

In early August 2026, XPEL, Inc. reported past second-quarter results showing year-over-year increases in revenue to US$143.05 million and net income to US$18.04 million, and issued third-quarter 2026 revenue guidance of approximately US$137 million to US$139 million. The company’s higher earnings per share alongside fresh revenue guidance offers investors clearer visibility into recent performance and near-term expectations. Next, we’ll examine how XPEL’s higher earnings per share guidance...
NYSE:MTDR
NYSE:MTDROil and Gas

The Bull Case For Matador Resources (MTDR) Could Change Following Strong Q2 Cash Flows And Higher 2026 Output

In the second quarter of 2026, Matador Resources Company reported revenue of US$1,186.39 million and net income of US$390.65 million, with higher oil and gas production versus a year earlier and earnings per share beating analyst expectations. The company also generated near-record adjusted free cash flow of US$303 million, used US$200 million to pay down debt, raised its full-year 2026 production guidance, and reported a 5% increase in proved reserves, extending its development runway...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

Travere Therapeutics (TVTX) Gets A Fresh Valuation Test As FILSPARI Fuels Q2 Revenue

Travere Therapeutics (TVTX) drew increased attention after reporting second quarter 2026 results, with revenue of US$169.58 million and a wider net loss of US$34.8 million as FILSPARI uptake expanded. See our latest analysis for Travere Therapeutics. At a share price of US$62.45, Travere Therapeutics has seen strong momentum build, with a 90 day share price return of 46.6% and a one year total shareholder return of 269.31% that reflects changing expectations around its rare kidney...